Asapiprant

DB20492InvestigationalSmall molecule

Asapiprant is a small molecule drug. Asapiprant is under investigation in clinical trial NCT04705597 (Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease... Asapiprant has a monoisotopic molecular weight of 501.16 Da.

Mechanism: Pharmacologically active on Prostaglandin D2 receptor
Curator reviewed
Formula / weight: C₂₄H₂₇N₃O₇S · 501.55 g/mol (avg)
Code names: BGE-175

Resolves to

Compound

UNIIB2LW71CRGLCAS932372-01-5ChEMBLCHEMBL3545043

Structure

InChIKeyZMZNWNTZRWXTJU-UHFFFAOYSA-NSMILESCC(C)OC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C1=CC(OCC(O)=O)=C(C=C1)C1=NC=CO1

Targets

Q13258PTGDR

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Asapiprant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account